AU2006246490B2 - Use of flumazenil in developing a drug for the treatment of alcohol dependence - Google Patents
Use of flumazenil in developing a drug for the treatment of alcohol dependence Download PDFInfo
- Publication number
- AU2006246490B2 AU2006246490B2 AU2006246490A AU2006246490A AU2006246490B2 AU 2006246490 B2 AU2006246490 B2 AU 2006246490B2 AU 2006246490 A AU2006246490 A AU 2006246490A AU 2006246490 A AU2006246490 A AU 2006246490A AU 2006246490 B2 AU2006246490 B2 AU 2006246490B2
- Authority
- AU
- Australia
- Prior art keywords
- flumazenil
- treatment
- alcohol
- administered
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 title claims description 153
- 229960004381 flumazenil Drugs 0.000 title claims description 151
- 238000011282 treatment Methods 0.000 title claims description 59
- 239000003814 drug Substances 0.000 title claims description 31
- 229940079593 drug Drugs 0.000 title description 15
- 208000007848 Alcoholism Diseases 0.000 title description 4
- 201000007930 alcohol dependence Diseases 0.000 title description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 75
- 238000000034 method Methods 0.000 claims description 31
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 claims description 11
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical group CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 claims description 10
- 229960004414 clomethiazole Drugs 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 235000019156 vitamin B Nutrition 0.000 claims description 9
- 239000011720 vitamin B Substances 0.000 claims description 9
- 229940046001 vitamin b complex Drugs 0.000 claims description 8
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 claims description 6
- 229960004526 piracetam Drugs 0.000 claims description 6
- 206010039897 Sedation Diseases 0.000 claims description 5
- 229960002563 disulfiram Drugs 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 230000036280 sedation Effects 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 229960002464 fluoxetine Drugs 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 230000009467 reduction Effects 0.000 description 10
- 208000029650 alcohol withdrawal Diseases 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 229940049706 benzodiazepine Drugs 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 208000019901 Anxiety disease Diseases 0.000 description 6
- 230000036506 anxiety Effects 0.000 description 6
- 150000001557 benzodiazepines Chemical class 0.000 description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 102000004300 GABA-A Receptors Human genes 0.000 description 4
- 108090000839 GABA-A Receptors Proteins 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000035487 diastolic blood pressure Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010012335 Dependence Diseases 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 229960003920 cocaine Drugs 0.000 description 3
- 230000001149 cognitive effect Effects 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 3
- 229960004134 propofol Drugs 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000011117 substance-related disease Diseases 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- 206010053164 Alcohol withdrawal syndrome Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012225 Delirium tremens Diseases 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108090000279 Peptidyltransferases Proteins 0.000 description 1
- ZGUGWUXLJSTTMA-UHFFFAOYSA-N Promazinum Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZGUGWUXLJSTTMA-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- -1 amino acids amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000000749 benzodiazepine receptor blocking agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229940085047 disulfiram 250 mg Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940083609 fluoxetine 20 mg Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002158 halazepam Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- NHMUJYOBLYTIKO-UHFFFAOYSA-L magnesium;[(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-methylamino]methanesulfonate Chemical compound [Mg+2].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1.O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 NHMUJYOBLYTIKO-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000663 medical toxicology Toxicity 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940088697 piracetam 800 mg Drugs 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960003598 promazine Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 230000003304 psychophysiological effect Effects 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
I
AUSTRALIA
Patents Act 1990 HYTHIAM, INC.
COMPLETE SPECIFICATION STANDARD PATENT Invention Title: Use offlumazenil in developing a drug for the treatment of alcohol dependence The following statement is a full description of this invention including the best method of performing it known to us:- O IA USE OF FLUMAZENIL IN DEVELOPING A DRUG FOR THE TREATMENT 0 OF ALCOHOL DEPENDENCE This application is a divisional application from Australian Patent Application No. 2002226427, the entire contents of which are incorporated herein by reference.
FIELD OF THE INVENTION SThe invention relates to the use of pharmaceutical compositions that contain C flumazenil in the treatment of alcohol dependency, more specifically to improvements in the use of flumazenil in the treatment of said dependency.
BACKGROUND OF THE INVENTION Alcohol dependency is a syndrome that develops in alcoholics who, all at once, stop consuming alcohol. Minor symptoms include tremor, weakness, sweats, and nausea. The most severe cases include convulsions and hallucinations. If untreated, alcohol withdrawal may cause delirium tremens.
The customary treatment of alcohol dependency includes the administration of vitamin B and C complexes, benzodiazepines (to calm agitation and to help prevent dependency), and, sometimes, disulfiram (to prevent alcohol use). A review of the various pharmacological treatments existing for the treatment of alcohol dependency can be found in A Practice Guideline for the Treatment of Patients With Substance Use Disorders: Alcohol, Cocaine and Opioids, produced by the Work Group on Substance Use Disorders of the American Psychiatric Association and published in Am. J.
Psychiatry 152:11, Nov. 1995 Supplement. An updated review of the treatment of alcohol dependency was made by Mayo-Smith et al., JAMA July 9, 1997, Vol. 278, No. 2, who conclude by indicating that the Sbenzodiazepines (alprazolam, diazepam, halazepam, lorazepam or oxazepam) are agents Z suitable for the treatment of alcohol dependency, whereas (3-blockers (propranolol), O neuroleptics (chlorpromazine and promazine), clonidine and carbamazepine, may be used in coadjuvant therapy, but their use is not recommended as a monotherapy. In none of the reviews mentioned is the use of flumazenil considered in the treatment of the alcohol withdrawal syndrome.
Flumazenil [ethyl 8-fluoro-5,6-dihydro-5-methyl-6-oxo-4H-imidazol[1,5- C a][l ,4]benzodiazepine-3-carboxylate] is a benzodiazepine antagonist which selectively blocks Sthe effects exerted on the central nervous system via the benzodiazepine receptors. This active Sprinciple is indicated to neutralize the central sedative effect of the benzodiazepines; consequently, it is regularly used in anesthesia to end the general anesthesia induced and maintained with benzodiazepines in hospitalized patients, or to stop the sedation produced with benzodiazepines in patients undergoing brief diagnostic or therapeutic procedures on an inpatient or outpatient basis.
Some clinical studies have examined the role of flumazenil in the reversal of alcohol withdrawal syndrome.
Gerra et al., 1991, Current Therapeutic Research, Vol. 50, 1, pp 62-66, describe the administration to 11 selected alcoholics (who did not have cirrhosis, metabolic disorders, convulsions, addictions to other substances or psychiatric disorders) of 2 mg/day of flumazenil divided into 4 doses (0.5 mg), intravenously in saline solution, every 6 hours for 48 hours, continuing the treatment with flumazenil for 2 more days. The use
IO
3 0 of 0.5 mg of flumazenil is based on the presentation of pharmaceutical preparations that contain said active principle, for example ANEXATE7 [sic] ROCHE, but not on studies c performed in humans concerning the level of occupation of the receptors involved. Taking into consideration the fact that the half-life of flumazenil in the human body is approximately O 45 minutes, the administration of 0.5 mg of flumazenil every 6 hours 0.08 mg/hour of flumazenil) does not seem adequate to effectively cover the cerebral benzodiazepine receptors (Savic et al., Lancet, 1991, 337, 133-137), which confirms what was stated by Gerra et al., loc.
cit., who, on page 64, next to last paragraph, state that they did not observe significant changes 0 in either the blood pressure or in the heart rate of the patients after the administration of CI flumazenil, which is surprising when there had been an effective interaction of the fumazenil administered with the cerebral benzodiazepine receptors. The tests performed by Gerr et al.
present some characteristics that are far from the actual circumstances, for example, the tests were performed on a small sample (11 individuals) of select patients not representative of the pathology considered since it is relatively customary that these patients have cirrhosis, metabolic disorders, convulsions, addictions to other substances (cocaine, heroin, etc.) and/or psychiatric disorders. Moreover, Gerra et al. do not present data concerning the evaluation of the dependency either before or after administration of the drug. The treatment with flumazenil, in accordance with the protocol developed by Gerra et al., lasts 4 days, which means a very long period of time which causes inconvenience for the patient as well as an increase in the cost and duration of the treatment.
o 4 Z Nutt et al. [Alcohol Alcoholism, 1993, Suppl. 2, pp 337-341. Pergamon Press Ltd.; Neuropschychopharmacology, 1994, Vol. 10, 35, part 1, Suppl., p. 85f) describe the administration to 8 alcoholics in the acute withdrawal phase of 2 mg of flumazenil, by IV, for 1 minute. This dosage was selected on the basis of studies that demonstrated that with said dose approximately 75% of the cerebral benzodiazepine receptors are occupied (Savic et al., ILancet, 1991, 337, 133-137). The results obtained after the administration of flumazenil were not completely satisfactory since in some cases, there was an immediate worsening of the withdrawal symptoms, especially of sweats and anxiety. In other cases, the withdrawal symptoms disappeared but returned a few hours later. Since flumazenil is metabolized and eliminated very quickly, the IV administration of a relatively high quantity of fumazenil in a single dose of 2 mg, for 1 minute, has several disadvantages since, on the one hand, it triggers side effects, and, on the other, some of the flumazenil administered yields no pharmacological response or a weak response which means an unacceptable expense.
The tests performed by Gerra et al. and by Nutt et al., loc. cit., with flumazenil to treat alcohol dependency do not provide representative results due to the use of a very small sample (only 19 patients tested of the approximately 600,000 patients treated annually in the United States during the years 1991-1994, years during which the work of Gerra et al. and of Nutt et al. occurred) which is not representative of said patients (the 11 patients treated in the trial of Gerra et al. were selected alcoholics who did not have cirrhosis, metabolic disorders,
O
0convulsions, addictions to other substances or psychiatric disorders). Moreover, the results obtained are not conclusive since in some cases, no significant changes were observed in either the blood pressure or the heart rate of patients after the administration offlumazenil (Gerra et al., loc. cit.); whereas, in other cases, an immediate worsening of the withdrawal Ssymptoms was observed, especially sweats and anxiety (Nutt et al., loc. cit.). These very Sdiscouraging results seem to have favored the abandonment of flumazenil as a therapeutic 0 agent for the treatment of alcohol dependency, a situation which could explain the absence of O publications of new trials associated with the treatment of alcohol dependency with flumazenil during the past 6 years as well as the failure to include said treatment in the aforementioned reviews concerning the treatment of alcohol dependency [A Practice Guideline for the Treatment of Patients With Substance Use Disorders: Alcohol, Cocaine and Opioids and Mayo-Smith et al.].
Consequently, it would be desirable to be able to determine without ambiguity whether flumazenil may be a suitable agent to treat alcohol dependency and, if so, to develop a protocol for administration of flumazenil for the treatment of alcohol dependency that would enable effectively eradicating the symptoms of alcohol withdrawal. It would also be desirable to reduce the quantity of flumazenil to be administered per dose during a short period of time for the purpose of reducing, on the one hand, the risk of undesirable side effects, and, on the other, to reduce or avoid unnecessary and pointless consumption of flumazenil.
0 BRIEF DESCRIPTION OF THE INVENTION SThe invention deals with the problem of developing a new method for the treatment of alcohol dependency based on safe and effective administration of flumazenil and which requires a short period of time to effectively eradicate the symptoms of alcohol dependency.
SThe solution provided by this invention is based on the use of pharmaceutical compositions that contain a therapeutically effective quantity of flumazenil for the treatment of alcohol dependency and the eradication of the symptoms of said syndrome \in a short period of time, with said pharmaceutical compositions containing small quantities of flumazenil and being intended for sequential administration.
C1 In one aspect, the present invention provides a method for treating alcohol dependency comprising administering an effective amount of flumazenil to a patient in need of treatment, wherein the flumazenil is administered sequentially in doses between about 0. 1 and 0.3 mg of flumazenil at time intervals between about 1 and minutes, and wherein the amount is effective to treat alcohol dependency.
In another aspect, the present invention provides a method for treating alcohol dependency comprising administering an effective amount of flumazenil to a patient in need of treatment, wherein the flumazenil is administered sequentially in doses between about 0.1 and 0.3 mg of flumazenil at time intervals between about 1 and minutes, wherein the amount is effective to treat alcohol dependency, and wherein the flumazenil reduces the desire to drink alcohol.
In a further aspect, the present invention provides a method for reducing the desire to drink alcohol in a patient in need of treatment comprising administering an effective amount of flumazenil to the patient, wherein the flumazenil is administered sequentially in doses between about 0.1 and 0.3 mg of flumazenil at time intervals between about I and 15 minutes, wherein the amount is effective to reduce the desire to drink alcohol in the patient.
In one embodiment, the effective amount of flumazenil is between about 1.5 and mg/day.
In another embodiment, the amount of flumazenil that is administered in each sequential administration is about 0.2 mg.
In another embodiment, the flumazenil is administered at intervals of about 3 minutes.
In another embodiment, the effective amount of flumazenil is about 2 mg/day.
1 In another embodiment, the flumazenil is administered orally or parenterally. In Sanother embodiment, the parenteral administration of flumazenil is intravenous administration.
00 In another embodiment, the flumazenil is administered at doses of about 0.2 mg of flumazenil at intervals of about 3 minutes until an effective amount of flumazenil O has been administered.
In another embodiment, the effective amount is about 2 mg/day.
In another embodiment, the flumazenil is administered before, during or after O treatment with an additional agent.
In another embodiment, the additional agent is clomethiazole.
C In another embodiment, the additional agent is selected from the group consisting of Vitamin B Complex, Piracetam, vitamins, minerals, proteins, amino acids, disulfiram, fluoxetine, and combinations thereof.
In another embodiment, the flumazenil is administered under sedation.
In another embodiment, the administration of flumazenil reduces the desire to drink alcohol.
Also provided is the use of flumazenil to prepare a medicament for treating alcohol dependency, wherein the medicament provides between about 0.1 and 0.3 mg of flumazenil and is sequentially administrable, at time intervals between about 1 and 15 minutes, wherein the amount is effective to treat alcohol dependency, and wherein the flumazenil reduces the desire to drink alcohol.
Also provided is the use of flumazenil to prepare a medicament for reducing the desire to drink alcohol in a patient, wherein the medicament provides between about 0.1 and 0.3 mg of flumazenil and is sequentially administrable, at time intervals between about 1 and 15 minutes.
Thus, another aspect of this invention consists in a method for the effective administration of flumazenil that uses a smaller quantity of drug per dose unit to be administered, by sequential administration of small quantities of flumazenil, to eradicate the symptoms of alcohol withdrawal in a short period of time, while simultaneously reducing the side effects caused by the administration of large quantities of the drug in a single application in a short period of time.
Another aspect of this invention consists in a method for the administration of flumazenil by sequential administration of small doses of flumazenil, without compromising its effects of eradication of the symptoms of alcohol withdrawal, effectively and reproducibly, in a short period of time.
613 Another additional aspect of this invention consists in the use of flumazenil to produce a drug for sequential administration, at short time intervals, of small quantities of flumazenil, until a therapeutically effective quantity to treat alcohol dependency has been administered.
Another additional aspect of this invention consists in a method for the O treatment of alcohol dependency that includes administration, to a patient in need of said treatment, of a therapeutically effective quantity of flumazenil, broken down into small quantities of flumazenil and intended for sequential administration, at short time \intervals, until said therapeutically effective quantity to treat alcohol dependency has been reached.
C In a further aspect, the present invention provides for the use of flumazenil to prepare a medicament for treating alcohol dependency, wherein the medicament provides between 0. 1 and 0.3 mg of flumazenil and is sequentially administrable, at time intervals between 1 and 15 minutes.
In a further aspect, the present invention provides for the use of flumazenil to prepare a medicament for treating alcohol dependency, wherein the medicament is O 7 sequentially administrable and provides about 0.2 mg of flumazenil at time intervals of 0 about 3 minutes, to provide up to about 2.0 mg of flumazenil per day.
Z In yet a further aspect, the present invention provides a method for treating C€ alcohol dependency, the method comprising administering to a patient in need of said treatment a therapeutically effective quantity of flumazenil, wherein the flumazenil is provided as individual dosages of between 0.2 and 0.3 mg, and dosages are administered sequentially at time intervals between I and 15 minutes, and wherein the IO sequential administration continues until when said therapeutically effective quantity of N flumazenil to treat alcohol dependency has been reached.
INO
In another aspect, the present invention provides a method for treating alcohol dependency, the method comprising administering to a patient in need of said treatment a therapeutically effective quantity of flumazenil of about 2 mg/day, wherein the flumazenil is provided as individual dosages of about 0.2 mg, and dosages are administered sequentially at time intervals of about 3 minutes, and wherein the sequential administration continues until when said therapeutically effective quantity of flumazenil to treat alcohol dependency has been reached.
The present invention also provides a medicament comprising pharmaceutical formulations when used for treatment of alcohol dependency, wherein each formulation comprises a dose of between 0. 1 and 0.3 mg of flumazenil and is sequentially administrable at time intervals between 1 and 15 minutes.
In another aspect, the present invention provides a medicament comprising pharmaceutical formulations when used for the treatment of alcohol dependency, wherein each formulation comprises a dose of about 0.2 mg of flumazenil and is sequentially administrable at time intervals of about 3 minutes to provide a total dose of up to about 2.0 mg of flumazenil per day.
In a further aspect, the present invention provides a pharmaceutical composition when used for the treatment of alcohol dependency comprising a dose of about 0.2 mg of flumazenil and a pharmaceutically acceptable carrier.
DETAILED DESCRIPTION OF THE INVENTION The invention relates to the use of flumazenil to produce a drug for sequential administration, at short time intervals, of small quantities of flumazenil, until a therapeutically effective quantity to treat alcohol dependency has been administered.
More specifically, the invention relates to the use of flumazenil to produce a drug for sequential administration, at time intervals between 1 and 15 minutes, of quantities of flumazenil between 0.1 and 0.3 mg, until a therapeutically effective I 7A
O
quantity, usually between 1.5 and 2.5 mg/day, of flumazenil has been administered, to 0 treat alcohol dependency.
SIn one embodiment, the invention relates to the use of flumazenil to produce a Sdrug for sequential administration, at intervals of 3 minutes, of 0.2 mg of flumazenil, until a therapeutically effective quantity of 2 mg/day of flumazenil has been cadministered, to treat alcohol dependency.
8 0 in the meaning used in this description, the term dhug includes the group of pharmaceutical compositions that contain fluniazenil, along with the pharmaceutically acceptable excipients suitable for the form of administration of said pharmaceutical compositions.
Although the trials described in the prior art associated with the treatment of alcohol dependency with flumazenil include the administration to the patient of an IV perfusion of 2 mg/day of flumazenil divided into 4 doses (0.5 mg/dose), every 6 hours for 48 hours, or 2 mg IND by IV for 1 minute, it was discovered, surprisingly, that flumazenil can be safely administered to said patients, in small quantities, applied sequentially and separated by a relatively short interval of time, until a therapeutically effective quantity of flumazenil to treat alcohol dependency has been reached.
This surprising discovery means that it is possible to administer flumazenil in smaller doses than was believed were necessary to obtain the desired therapeutic response, which reduces the risk of secondary effects in the patient (as a result of reducing the quantity of drug administered per dose applied), on the one hand, and, on the other, provides a better use of flumazenil to treat the symptoms of alcohol withdrawal and to reduce the unnecessary and pointless consumption of said drug (which increases convenience and the quality of life of the patient and reduces cost) to treat alcohol dependency in a very short period of time.
Example I demonstrates that the admidnistration to patients of 2 mg/day of flumazenil divided into doses of 0.2 mg every 3 minutes eradicates the symptoms of alcohol withdrawal in a high percentage of the patients treated.
S9 0 Z Consequently, in one embodiment, the invention relates to the use of flumazenil to produce a drug for administration, sequentially, of 0.2 mg of flumazenil every 3 minutes, up to a quantity of 2 mg/day, to treat alcohol dependency.
Flumazenil may be administered by any appropriate route of administration, for example, orally or parenterally, for which it will be formulated with the appropriate excipients Sfor the form of administration to be used. In one embodiment, flumazenil is administered by
SIV.
SThe invention also relates to a method for the treatment of alcohol dependency that 0includes the administration to a patient in need of said treatment of a therapeutically effective quantity of flumazenil, usually between 1.5 and 2.5 mg/day of flumazenil, broken down into quantities of flumazenil between 0.2 and 0.3 mg and intended for sequential administration, at time intervals between 1 and 15 minutes, until said therapeutically effective quantity of flumazenil to treat alcohol dependency has been reached.
Flumazenil may be administered by any appropriate route of administration, for example, orally or parenterally, for which it will be formulated with the appropriate excipients for the form of administration to be used. In one embodiment, flumazenil is administered by
IV.
The method for the treatment of alcohol dependency provided by this invention is applicable to any patient who, when the treatment is to begin, has no acute or uncompensated illness, or is not taking medication contraindicated with flumazenil. In general, the method of treatment of alcohol dependency provided by this invention o begins with a complete medical and psychological examination. Before and after Z administration of flumazenil, the symptoms of alcohol withdrawal, heart rate, and O blood pressure are evaluated. If the patient presents an anxiety crisis, it is possible to administer an appropriate therapeutic agent, for example, clomethiazole, before administration of flumazenil. Likewise, if the patient presents a severe diagnosis of benzodiazepine dependency, the first administration of flumazenil is carried out under IDsedation, for example, with propofol, under intensive care conditions. The Ni administration of flumazenil may be carried out orally or intravenously, for example, by boluses that contain the appropriate quantity and under observation of the patient's reaction. Once inpatient treatment has concluded, as part of the therapeutic program, the patient must continue pharmacological treatment and continue sessions with his therapist to evaluate his progress. The treatment is supplemented by a semistructured follow-up of the cognitive behavior of the patient.
Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is solely for the purpose of providing a context for the present invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application.
Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
The following example demonstrates the invention and must not be considered to limit the scope thereof.
EXAMPLE 1 Treatment of patients with flumazenil sequentially and at low dose 1.1 Experimental Protocol 64 alcoholics (51 males and 13 females) voluntarily entered a treatment program to discontinue the use of alcohol. Said patients were provided the appropriate information and the corresponding informed consent form was obtained 11 z from them. The patients were warned not to drink alcohol the morning on which the treatment Swas to be carried out to enable better evaluation of the withdrawal symptoms.
c Table 1 summarizes the characteristics of the patients treated associated with alcohol use.
Table 1 Characteristics of the patients associated with alcohol use 0 Mean SD Minimum Maximum Age (years) 42.7 10.2 20 Age at the beginning of daily alcohol 24.6 10.2 6 71 use (years) Daily units of alcohol intake 24.9 15.4 4 73 Y-glutamyl transpeptidase 159.1 227.2 12 1.230
(GGT)
Corpuscular volume 97.8 6.4 72 111 Number of previous detoxifications 1.6 1.2 0 [SD: Standard deviation]
NOTE:
consumed alcohol daily and 39.1% consumed benzodiazepines daily.
IO
0 12 Before starting the treatment, the patients underwent a complete medical and Spsychological examination. The monitoring of the patients throughout the morning included a complete blood count, a biochemical profile [creatinine, glucose, urea, cholesterol (HDL and SLDL), triglycerides, alkaline phosphatase, LDH (lactic dehydrogenase) and total proteins], hepatic function tests [GOT, GPT, GGT, bilirubin), electrocardiogram and, if need be, pregnancy test and x-ray examination. The exclusion criteria applied included acute or \0 uncompensated illnesses, as well as the taking of any drug contraindicated with flumazenil.
No patient was excluded after the pre-admission interview and the tests performed. Admission C' of one patient was postponed until his cardiac pathology was checked.
Before and after the administration of flumazenil, the withdrawal symptomatology was measured using the CIWA-A evaluation (Adinoff et al., Medical Toxicology 3:172-196 (1988)), as well as heart rate and blood pressure.
Table 2 presents the treatment protocol followed during hospitalization.
13 Table 2 Protocol followed during hospitalization Time Day of admission Day 2 Day of discharge 9:00 a.m. Clomethiazole 192 mg Clomethiazole 192 mg Vitamin B Complex Vitamin B Complex Piracetam 3 g (oral) Piracetam 3 g (oral) Drink with vitamins, Drink with vitamins, minerals, proteins, and minerals, proteins, and amino acids amino acids 11:00 a.m. Flumazenil 2 mg 1:00 p.m. Clomethiazole 192 mg Vitamin B Complex Piracetam 3 g (oral) 4:30 p.m. Flumazenil 2 mg 7:30 p.m. Vitamin B Complex Vitamin B Complex Disulfiram 250 mg 9:30 p.m. Clomethiazole 384 mg Clomethiazole 384 mg Flumazenil was administered at a dose of 0.2 mg every 3 minutes (up to a total of 2 mg/day), because of the fact that the effects of flumazenil can be detected after 1-2 minutes after their administration. This quantity per dose was established to minimize the adverse side effects associated with withdrawal or interactions with other pharmaceuticals or psychopathologies. By administration of 2 mg of flumazenil per day, more than 55% of the GABA receptors were occupied.
Patients who presented marked anxiety were administered an additional dose of 192 mg of clomethiazole 30 minutes before administration of flumazenil. In those patients who presented a severe diagnosis of benzodiazepine dependency, the initial administration of
O
O
14 O flumazenil was performed under sedation with propofol under intensive care conditions.
Before discharge from the hospital, the following medications were prescribed: CC Vitamin B complex: 1 month 1-1-0 (breakfast-lunch-dinner); Piracetam 3 g: 1 week 1-0-0; piracetam 800 mg: 1 month 1-1-0; 0 Fluoxetine 20 mg: 2 months 1-0-0; Clomethiazole 192 mg: 1 week 1-0-1, and reduction to 0-0-0 during the second week; and Disulfuram 250 mg 1-0-0.
SAs part of the treatment program, the patients were instructed to attend the outpatient C treatment center for 9 months with decreasing frequency [once a week for the first three months, once every two weeks during the second three months, and once a month during the third three months].
Likewise, a semistructured follow-up of cognitive behavior was implemented.
Individual and family psychotherapy was focused on 4 major interventions (cognitive restructuring, work therapy, prevention of relapse, and stress reduction) aimed at rehabilitating the social, family, work, personal and leisure life of the patient.
1.2 Results Of the 64 patients treated, in 3 cases, the first administration of flumazenil was interrupted and postponed to the following day: one of them, who was obviously intoxicated with alcohol, demonstrated a distressing increase in confusion, another had a significant increase in distal tremors, and the other, who was also addicted to 0 z benzodiazepines, demonstrated a significant increase in anxiety. Another group of 3 patients received the first dose of flumazenil under sedation with propofol in the intensive care unit.
Approximately 10% of the patients suffered headache during or immediately following the administration of flumazenil, which disappeared after a few minutes, or after administration of metamizole magnesium.
Results after the first administration of flumazenil The CIWA-A scoring of 55 patients showed that: \47.3% had a significant reduction -7.713; p<.000); 040.0% experienced no change; and 12.7% had a significant increase 2.511; p<.0 4 6 [in the three cases presenting the greatest increase, the treatment was discontinued].
The heart rate values of 55 patients showed that: 50.9% had a significant reduction -8.820; p<.000); 40.0% experienced no change; and 9.1% had a significant increase 4.750; p<.009).
The systolic blood pressure values of 53 patients showed that: 47.2% had a significant reduction -9.908; p<.000); 37.7% experienced no change; and 15.1% had a significant increase 4.314; p<.004).
IO
16 0 Z The diastolic blood pressure values of 53 patients showed that: 34% had a significant reduction -9.220; p<.000); Cc, 47.2% experienced no change; and 18.9% had a significant increase 5.511; p<.000).
M\ Results after the second administration of flumazenil SThe CIWA-A scoring of 58 patients showed that: S36.2% had a significant reduction -5.363; p<.000); S55.2% experienced no change; and 8.6% had a significant increase 4.000; p<.016).
The heart rate values of 55 patients showed that: 41.8% had a significant reduction -8.523; p<.000); and 58.2% experienced no change.
The systolic blood pressure values of 56 patients showed that: 28.6 had a significant reduction -7.596; p<.000); 55.4% experienced no change; and 16.1% had a significant increase 4.612; p<.00 2 0 0 17
O
Z The diastolic blood pressure values of 56 patients showed that: 0 28.6% had a significant reduction -6.325; p<.000); 51.8% experienced no change (n 29); and 19.6% had a significant increase 6.640; p<.000).
\Table 3 statistically summarizes the results obtained before and after the treatment (at the end of 18 hours).
IN
18 Table 3 Statistical summary of the results Obtained before and after the treatment (at the end of 18 hours) X N SD EM T Sig CIWA-A 4.13 54 4.28 0.58 6.190 0.002 Before Treatment CIWA-A 0.76 54 1.52 0.21 After Treatment Systolic Blood Pressure 135.20 51 18.22 2.55 5.256 0.000 Before Treatment Systolic Blood Pressure 126.67 51 13.99 1.96 After Treatment Diastolic Blood Pressure 86.27 51 10.76 1.51 3.273 0.002 Before Treatment Diastolic Blood Pressure 82.75 51 9.13 1.28 After Treatment Heart Rate 81.42 53 13.83 1.90 4.273 0.000 Before Treatment___ Heart Rate 75.02 53 9.93 1.36 After Treatment Mean; N: Number of samples; SD: Standard deviation; EM: Mean error; T: Student's factor; Sig: Significance] Table 4 summarizes the follow-up data.
Table 4 Summary of Follow-up Month 1 Month 3 Month 6 Month 9 67.2/43 34.4/22 18.8/12 12.5/8 Therapy and Disulfiram 95.3% 86.4% 75.0% 75.0% Therapy without Disulfiram 4.5% 12.5% Dropouts 4.7% 9.1% 25.0% 12.5% IND 19 o The psychophysiological functions such as appetite and sleep were regained Svery rapidly during hospitalization.
SThe second day of hospitalization, the patients were permitted to spend a few hours outside the clinic during the afternoon. Some patients had dinner outside the clinic.
SProbably, the most striking result is the spontaneous verbal report from the IN majority of the patients concerning the absence of anxiety and of the desire to drink C alcohol.
110
Claims (12)
1. A method for treating alcohol dependency comprising administering an effective 00 amount of flumazenil to a patient in need of treatment, wherein the flumazenil is administered sequentially in doses between about 0.1 and 0.3 mg of flumazenil at time O intervals between about 1 and 15 minutes, and wherein the amount is effective to treat "t alcohol dependency. S2. A method for treating alcohol dependency comprising administering an effective amount of flumazenil to a patient in need of treatment, wherein the flumazenil is (1 administered sequentially in doses between about 0.1 and 0.3 mg of flumazenil at time intervals between about I and 15 minutes, wherein the amount is effective to treat alcohol dependency, and wherein the flumazenil reduces the desire to drink alcohol.
3. A method for reducing the desire to drink alcohol in a patient in need of treatment comprising administering an effective amount of flumazenil to the patient, wherein the flumazenil is administered sequentially in doses between about 0.1 and 0.3 mg of flumazenil at time intervals between about 1 and 15 minutes, wherein the amount is effective to reduce the desire to drink alcohol in the patient.
4. The method according to any one of claims 1 to 3, wherein the effective amount of flumazenil is between about 1.5 and 2.5 mg/day. The method according to any one of claims 1 to 4, wherein the amount of flumazenil that is administered in each sequential administration is about 0.2 mg.
6. The method according to any one of claims I to 5, wherein the flumazenil is administered at intervals of about 3 minutes.
7. The method according to any one of claims 1 to 6, wherein the effective amount of flumazenil is about 2 mg/day.
8. The method according to any one of claims I to 7, wherein the flumazenil is administered orally or parenterally. 21 S9. The method according to any one of claims 1 to 7, wherein the parenteral administration of flumazenil is intravenous administration. 00 The method according to any one of claims 1 to 9, wherein the flumazenil is administered at doses of about 0.2 mg of flumazenil at intervals of about 3 minutes Suntil an effective amount of flumazenil has been administered. S1i. The method of claim 10, wherein the effective amount is about 2 mg/day. tI
12. The method according to any one of claims 1 to 11, wherein the flumazenil is administered before, during or after treatment with an additional agent.
13. The method of claim 12, wherein the additional agent is clomethiazole.
14. The method of claim 13, wherein the additional agent is selected from the group consisting of Vitamin B Complex, Piracetam, vitamins, minerals, proteins, amino acids, disulfiram, fluoxetine, and combinations thereof. The method according to any one of claims 1 to 14, wherein the flumazenil is administered under sedation.
16. The method of claim 1, wherein the administration of flumazenil reduces the desire to drink alcohol.
17. Use of flumazenil to prepare a medicament for treating alcohol dependency, wherein the medicament provides between about 0. 1 and 0.3 mg of flumazenil and is sequentially administrable, at time intervals between about I and 15 minutes, wherein the amount is effective to treat alcohol dependency, and wherein the flumazenil reduces the desire to drink alcohol.
18. Use of flumazenil to prepare a medicament for reducing the desire to drink alcohol in a patient, wherein the medicament provides between about 0. 1 and 0.3 mg of flumazenil and is sequentially administrable, at time intervals between about I and minutes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2006246490A AU2006246490B8 (en) | 2000-03-10 | 2006-11-30 | Use of flumazenil in developing a drug for the treatment of alcohol dependence |
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPQ6165A AUPQ616500A0 (en) | 2000-03-10 | 2000-03-10 | System for automated generation of professional documents |
| ESP200100106 | 2001-01-17 | ||
| ES200100106 | 2001-01-17 | ||
| PCT/ES2002/000008 WO2002056964A1 (en) | 2001-01-17 | 2002-01-10 | Use of flumazenil in developing a drug for the treatment of alcohol dependence |
| AU2002226427A AU2002226427B2 (en) | 2001-01-17 | 2002-01-10 | Use of flumazenil in developing a drug for the treatment of alcohol dependence |
| AU2006246490A AU2006246490B8 (en) | 2000-03-10 | 2006-11-30 | Use of flumazenil in developing a drug for the treatment of alcohol dependence |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002226427A Division AU2002226427B2 (en) | 2000-03-10 | 2002-01-10 | Use of flumazenil in developing a drug for the treatment of alcohol dependence |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2006246490A1 AU2006246490A1 (en) | 2006-12-21 |
| AU2006246490B2 true AU2006246490B2 (en) | 2008-10-23 |
| AU2006246490B8 AU2006246490B8 (en) | 2008-11-13 |
Family
ID=40032469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006246490A Ceased AU2006246490B8 (en) | 2000-03-10 | 2006-11-30 | Use of flumazenil in developing a drug for the treatment of alcohol dependence |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2006246490B8 (en) |
-
2006
- 2006-11-30 AU AU2006246490A patent/AU2006246490B8/en not_active Ceased
Non-Patent Citations (2)
| Title |
|---|
| Nutt et al, Alcohol & Alcoholism. 1992. Suppl. 2, pages 337-341 * |
| Potokar et al, Alcohol & Alcoholism. 1997. 32(5) pages 605-611 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006246490B8 (en) | 2008-11-13 |
| AU2006246490A1 (en) | 2006-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080132492A1 (en) | Use of Flumazenil in the Production of a Drug for the Treatment of Alcohol Dependency | |
| US4229447A (en) | Intraoral methods of using benzodiazepines | |
| US20070142364A1 (en) | Flumazenil for the Treatment of Cocaine Dependency | |
| KR20080004581A (en) | How to treat anxiety-related disorders | |
| JP2004519461A5 (en) | ||
| JP2004521904A5 (en) | ||
| AU2006246490B2 (en) | Use of flumazenil in developing a drug for the treatment of alcohol dependence | |
| HK1061661B (en) | Use of flumazenil in developing a drug for the treatment of alcohol dependence | |
| AU2006200922A1 (en) | Use of flumazenil to produce a medicament for the treatment of cocaine dependency | |
| Marken | Flumazenil: A Unique Medication to Reverse the Effects of Benzodiazepines | |
| HK1061817B (en) | Use of flumazenil to produce a medicament for the treatment of cocaine dependency |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH | Corrigenda |
Free format text: IN VOL 22, NO 42, PAGE(S) 4994 UNDER THE HEADING APPLICATIONS ACCEPTED -NAME INDEX UNDER THE NAME HYTHIAM, INC., APPLICATION NO. 2006246490, UNDER INID(72), CORRECT THE INVENTOR NAME TO LEGARDA IBANEZ, JUAN JOSE |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |